Scinai Immunotherapeutics Ltd. Sponsored Adr (SCNI) has released an update.
Scinai Immunotherapeutics Ltd. has reported a comprehensive financial performance for FY 2023 and has provided updates on its business endeavors, including advances in its pipeline development and the growth of its CDMO business unit. The company has raised funds through warrant exercises and an Israel Innovation Authority grant, and it anticipates increased CDMO revenues following active marketing and new client engagements. Additionally, Scinai has announced significant preclinical achievements with its NanoAb program, targeting various autoimmune diseases, and is planning strategic partnerships and clinical trials.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
